In the ongoing battle against COVID-19, the World Health Organization's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) plays a crucial role in guiding vaccine development and strategy. Their recent meeting in May 2026 focused on reviewing the latest SARS-CoV-2 evolution and vaccine effectiveness, leading to some intriguing insights and recommendations.
The TAG-CO-VAC's Role and Findings
TAG-CO-VAC's primary objective is to enhance vaccine-induced immune responses to SARS-CoV-2 variants. In their May meeting, they advised vaccine manufacturers to use monovalent LP.8.1 as the recommended vaccine antigen. This decision was based on evidence of its effectiveness against circulating variants, particularly the predominant Variant Under Monitoring (VUM) XFG.
However, the TAG-CO-VAC also acknowledged the emergence of other variants, such as VUM NB.1.8.1 in the Western Pacific Region, and the increasing proportion of VUM BA.3.2 globally. These variants present unique antigenic characteristics, with BA.3.2 showing lower fitness compared to JN.1-descendant variants.
Immunogenicity and Vaccine Effectiveness
Immunogenicity data revealed that LP.8.1 induces broadly cross-reactive immune responses in populations with high prior infection and/or vaccination rates. Sera from vaccinated individuals demonstrated significant increases in neutralizing activity against JN.1 and its descendants, including NB.1.8.1 and XFG. However, post-vaccination responses against BA.3.2 were lower, indicating its antigenic distinctness.
Vaccine effectiveness estimates also supported the use of monovalent LP.8.1, demonstrating additional protection against symptomatic and severe COVID-19. While data on other vaccines is limited, the TAG-CO-VAC emphasized the importance of continued surveillance and data generation to inform future decisions.
Recommendations and Future Directions
Based on their findings, the TAG-CO-VAC recommended monovalent LP.8.1 as the primary vaccine antigen. However, they also acknowledged the potential use of other antigens, such as XFG or NB.1.8.1, if they demonstrate broad and robust neutralizing antibody responses.
Looking ahead, the TAG-CO-VAC highlighted several areas for further investigation, including:
- Immune responses and clinical endpoints in varied populations receiving approved vaccines against emerging variants.
- Strengthened epidemiological and virological surveillance to track variant displacement and disease severity, particularly in immunologically naïve individuals.
- Non-clinical and clinical immunogenicity data for vaccine candidates with different SARS-CoV-2 antigens.
Conclusion: A Dynamic Approach to Vaccine Strategy
The TAG-CO-VAC's work showcases the dynamic nature of vaccine strategy in the face of a rapidly evolving virus. Their recommendations are not static, but rather adapt to the latest scientific evidence and surveillance data.
As we continue to navigate the COVID-19 pandemic, the TAG-CO-VAC's ongoing monitoring and guidance will be crucial in ensuring that vaccine strategies remain effective and tailored to the ever-changing landscape of SARS-CoV-2 variants. Their work underscores the importance of global collaboration and data sharing in our collective fight against this virus.
